Prof. Hong Cen 岑洪
Chief Physician, Professor
Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of lymphoma, leukemia, multiple myeloma, and nasopharyngeal carcinoma. Specializes in hematopoietic stem cell transplantation for lymphohematopoietic tumors and chemotherapy-sensitive solid tumors.
Dr. Cen holds a doctoral degree and serves as Chief of the Department of Medical Oncology and Chief of the Department of Lymphohematologic and Pediatric Oncology at Guangxi Medical University Cancer Hospital. With over 20 years of experience in medical oncology, Dr. Cen has extensive clinical expertise in diagnosing and treating various cancers.
Professional roles
- Vice Chair, Oncology Drug Therapy Physicians Branch, Guangxi Medical Doctor Association
- Chair, Lymphoma Professional Committee, Guangxi Anti-Cancer Association
- Vice Chair, Chemotherapy Professional Committee, Guangxi Anti-Cancer Association
- Standing Committee Member, Biological Therapy Professional Committee, Guangxi Anti-Cancer Association
Name order: in Chinese the family name comes first (Cen Hong). Papers usually list the name as Hong Cen or Cen H.
Selected publications
13 papers on PubMed matched by name and affiliation; 4 as first or senior author since 2016. Most recent first- or senior-author papers:
- Heliyon, 2024 (senior author): Prognostic model based on M2 macrophage-related signatures for predicting outcomes, enhancing risk stratification, and providing therapeutic insights in diffuse large B-cell lymphoma. PubMed 39759325
- Front Oncol, 2024 (senior author): Baseline and interim (18)F-FDG PET/CT metabolic parameters predict the efficacy and survival in patients with diffuse large B-cell lymphoma. PubMed 39435282
- J Cancer, 2024 (senior author): Comparison of the Efficacy and Safety of Axi-Cel and Tisa-Cel Based on Meta-Analysis. PubMed 39308670
- PLoS One, 2020 (senior author): EZH2 is a negative prognostic biomarker associated with immunosuppression in hepatocellular carcinoma. PubMed 33180829
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion